key: cord-0885406-42pdktb9
authors: Hariyanto, Timotius Ivan; Kurniawan, Andree
title: Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression
date: 2021-02-27
journal: Nutr Metab Cardiovasc Dis
DOI: 10.1016/j.numecd.2021.02.020
sha: 123f92bcfbdca0fae84cde67d1f681cfe866ef9b
doc_id: 885406
cord_uid: 42pdktb9

Background and aims One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and composite poor outcomes of COVID-19. Methods We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until November 25th, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 and Comprehensive Meta-Analysis 3 software. Results A total of 35 studies with a total of 11,930,583 patients were included in our analysis. Our meta-analysis showed that statin use did not improve the composite poor outcomes of COVID-19 [OR 1.08 (95% CI 0.86 – 1.35), p = 0.50, I 2 = 98%, random-effect modelling]. Meta-regression showed that the association with composite poor outcomes of COVID-19 was influenced by age (p = 0.010), gender (p = 0.045), and cardiovascular disease (p = 0.012). Subgroup analysis showed that the association was weaker in studies with median age ≥60 years-old (OR 0.94) compared to <60 years-old (OR 1.43), and in the prevalence of cardiovascular disease ≥25% (RR 0.94) compared to <25% (RR 1.24). Conclusion Statin use did not improve the composite poor outcomes of COVID-19. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes.

In March 2020, the World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID- 19) as global pandemic disease, and now nine months after that, the number of positive and death cases from COVID-19 is still increasing. The reported manifestation of COVID-19 can range from mild respiratory symptoms such as fever and cough to severe and potentially lethal symptoms such as sepsis, arrhythmia, heart failure, and loss of consciousness. [1] Several meta-analysis have demonstrated that patients' comorbid conditions such as dyslipidemia was associated with the development of severe outcomes and mortality from COVID-19. [2] [3] [4] [5] [6] [7] [8] Most of the patients with dyslipidemia will take statin as their daily medications. Statin belong to a HMG-CoA reductase inhibitor drugs that has been long known as an effective cholesterol-lowering agent. Previous studies have proposed that statin may be beneficial in improving the outcome of COVID-19. [9, 10] The beneficial effects of statin may be related to its pleiotropic properties. This pleiotropic property of statin is believed to reduce the burden of obesity, cardiovascular disease, and dyslipidemia which are associated with poor outcomes of COVID-19. Statin can impair the virus's ability to infect cells and reducing its infectivity through down-regulation of CD147 in human cells, including pulmonary cells. [9] Statin can also prevent or reverse host cell lipid raft alterations induced by COVID-19 infection, which can reduce both cell infection and viral replication.

Moreover, pleiotropic properties of statin can exert anti-inflammatory effects by inhibiting NLRP3 inflammasome through the TLR4/MyD88/NF-κB pathway, therefore restraining the uncontrolled inflammation which can be fatal in COVID-19 patients. [9] In silico study by Reiner et al. [10] showed that statin may be an effective SARS-CoV-2 Mpro inhibitors based on its binding energy which is higher than protease or polymerase inhibitors. However, all of these arguments are not yet supported by sufficient in human studies. This study aims to analyze the association between statin use and outcomes from COVID-19.

J o u r n a l P r e -p r o o f

Studies were included in this review if met the following inclusion criteria: representation for clinical questions (P: positive/confirmed cases of COVID-19; I: a group of patients who take statin as their medications; C: a group of patients who did not use statin; O: composite poor outcomes which comprise of risk COVID-19, severe COVID-19, and mortality), type of study was a randomized control trial, cohort, clinical trial, case-cohort, and cross-over design, and if the full-text article was available. The following types of articles were excluded: articles other than original research (e.g., review articles, letters, or commentaries); case reports; articles not in the English language; articles on research in pediatric populations (17 years of age or younger); and articles on research in pregnant women.

A systematic search of the literature was conducted on PubMed and Europe PMC using the keywords "statin" OR "lipid-lowering drugs" OR "lipid-lowering agents" AND "coronavirus disease 2019" OR "COVID-19", between 2019 and present time (October 25 th , 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of statin use in COVID-19 patients with a clinically validated definition of each component of the outcomes of interest were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles. The study was carried out per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. [11] J o u r n a l P r e -p r o o f

Data extraction was performed independently by two authors, we used standardized forms that include author, year, study design, number of participants, age, gender, hypertension, diabetes, cardiovascular disease, statin use, and proportion of patients with each outcome of COVID-19. was defined as patients who had any of the following features at the time of, or after, admission: (1) respiratory distress (≥30 breaths per min); (2) oxygen saturation at rest ≤93%;

(3) ratio of the partial pressure of arterial oxygen (PaO2) to a fractional concentration of oxygen inspired air (fiO2) ≤300 mmHg; or (4) critical complication (respiratory failure, septic shock, and or multiple organ dysfunction/failure) or admission into ICU. Mortality outcome from COVID-19 was defined as the number of patients who were dead because of COVID-19 infection.

Two investigators independently evaluated the quality of the included cohort and case-control studies using the Newcastle-Ottawa Scale (NOS). [12] The selection, comparability, and exposure of each study were broadly assessed and studies were assigned a score from zero to nine. Studies with scores ≥7 were considered of good quality.

A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) and Comprehensive Meta-Analysis version 3 software. We used the Generic Inverse Variance formula with random-effects models to calculate each outcome's risk. The

Studies with various study designs including cohort and case-control were included in this review and assessed accordingly with the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the cohort and case-control studies ( Table 2 ). All included studies were rated 'good'. In conclusion, all studies were seemed fit to be included in the meta-analysis.

Our pooled analysis showed that statin was not associated with composite poor 

Meta-regression showed that the association between statin and composite poor outcome was affected by age (p = 0.010) ( Figure 3A ), gender (p = 0.045) ( Figure 3B ), and cardiovascular disease (p = 0.012) ( Figure 3C ), but not affected by hypertension (p = 0.610) and diabetes mellitus (p = 0.246).

Subgroup analysis for studies with median age ≥60 years [ 

The funnel-plot analysis showed a qualitatively symmetrical inverted funnel-plot for the association between statin and composite poor outcome (Figure 4) , showing no indication of publication bias.

Previous meta-analysis that showed the benefit of statin in reducing the disease severity and/or mortality from COVID-19 only involved 4 studies and did not elaborate the effects of the confounding factors which can affect the relationship between statin use and J o u r n a l P r e -p r o o f outcome of COVID-19, such as age, gender, and comorbid conditions, resulting in weak and preliminary conclusions. [47] Our systematic review and meta-analysis already involved 35 included studies and not only analyzes the association between statin use and composite poor outcomes of COVID-19, but also elaborate the effect of the confounding factors such as age, gender, and comorbid conditions. This comprehensive meta-analysis of 35 studies showed that statin use was not associated with composite poor outcomes of COVID-19 which comprised of risk of COVID-19, severe COVID-19, and mortality from COVID-19. This association was influenced by age, gender, and cardiovascular disease. Further analysis based on meta-regression showed that magnitude of risk linked to statin use as a single factor was greater in studies with younger, non-male dominant, and low prevalence of cardiovascular disease patients, which is yet to be addressed by the existing literature.

Several reasons can be proposed to explain why statin use did not improve the outcomes from COVID-19. First, apart from its beneficial effects through pleiotropic properties, the action of statin on TLR and NF-κB signaling also carry the potential risk of exacerbating compensatory immune signals and poor disease outcome. [48] This theory is supported by a retrospective analysis of the findings from a multicenter clinical trial on the efficacy of rosuvastatin against infection-induced ARDS that showed higher IL-18 levels and mortality in statin-treated patients. [49] Second, based on the experimental studies in animal models, statin therapy may upregulate the expression of angiotensin-converting enzyme 2 (ACE2), which mediates the SARS-CoV-2 entry into host cells, thus can increase its viral load and infectivity, resulting in severe outcome of the disease. [50, 51] Third, statin may cause hepatotoxicity and myotoxicity in some patients that can cause acute kidney injury.

Moreover, this adverse effect of statin is higher in older patients and may be exacerbated when given concomitantly with antiviral agents for COVID-19 such as lopinavir and J o u r n a l P r e -p r o o f darunavir. [52, 53] Statins are a substrate for cytochrome P450 (CYP) system, especially 3A isoenzymes and P-glycoproteins (P-gp), while protease inhibitors, such as lopinavir and darunavir are potent inhibitors of both CYP3A and P-gp, so their concomitant administration will result in markedly statin exposure and adverse effects. [48, 54] Therefore, the beneficial effects of statin may be counter-balanced by its potentially harmful effects and causing a neutral effect toward COVID-19. Finally, the anti-inflammatory effects of statin are relatively lower than corticosteroids [55] , making statin cannot make a significant alteration in the inflammation or cytokine storm that happened in COVID-19, thus the composite poor outcomes of COVID-19 was not altered by statin administration.

Patients with dyslipidemia and cardiovascular disease should hence be advised to still continue taking statin during the COVID-19 pandemic given its pleiotropic effects which offer benefit in reducing the cardiovascular adverse events and its neutral effects toward This study has several limitations. First, data on the dosage and duration of statin therapy were lacking in the included studies, hence, cannot be analyzed. Second, we include some pre-print studies to minimize the risk of publication bias, however, the authors have made exhaustive efforts to ensure that only sound studies were included and we expect that most of those studies currently available in pre-print form will eventually be published and that we will identify them through ongoing electronic literature surveillances. We hope that this study can give further insight into statin therapy in COVID-19 patients. Alamdari NM et al. [12] 2020 Cohort *** ** *** 8 Good

An C et al. [13] 2020 Cohort *** ** *** 8 Good

Argenziano MG et al. [14] 2020 Cohort *** ** *** 8 Good

Ayed M et al. [15] 2020 Cohort *** ** *** 8 Good

Bifulco M et al. [16] 2020 Cohort *** ** ** 7 Good

Cariou B et al. [17] 2020 Cohort *** ** **** 9 Good

Daniels LB et al. [18] 2020 Cohort *** ** *** 8 Good

De Spiegeleer AD et al. [19] 2020 Cohort *** ** *** 8 Good

Dreher et al. [20] 2020 Cohort ** ** *** 7 Good

Gupta A et al. [21] 2020 Cohort *** ** **** 9 Good

Higuchi T et al. [22] 2020 Cohort *** ** *** 8 Good

Hippisley-Cox J et al. [23] 2020 Cohort *** ** *** 8 Good

Ho F et al. [24] 2020 Cohort *** ** *** 8 Good

Holman N et al. [25] 2020 Cohort **** ** *** 9 Good

Huh K et al. [26] 2020 Case-control *** ** *** 8 Good

Inciardi RM et al. [27] 2020 Cohort *** ** *** 8 Good

Israel A et al. [28] 2020 Cohort *** ** *** 8 Good

Izzi-Engbeaya C et al. [29] 2020 Cohort *** ** *** 8 Good

Kibler M et al. [30] 2020 Cohort *** ** *** 8 Good

Lala A et al. [31] 2020 Cohort *** ** **** 9 Good

Luo P et al. [32] 2020 Cohort ** ** *** 

Coronavirus disease 2019 and cardiovascular system: A narrative review

Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection

Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection

Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection

Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A Systematic Review and Meta-Analysis

Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection

Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection. Eur Arch Psychiatry Clin Neurosci

Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis

Statins: Could an old friend help in the fight against COVID-19?

Statins and the COVID-19 main protease: in silico evidence on direct interaction

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major

Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in J o u r n a l P r e -p r o o f New York: retrospective case series

Assessment of clinical characteristics and mortality-associated factors in COVID-19 Critical cases in Kuwait

The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS

Patients with COVID-19. Res Sq

Early Clinical Factors Predicting the Development of Critical Disease in Japanese Patients with COVID-19: A Single-Center, Retrospective, Observational Study

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Association of previous medications with the risk of COVID-19: a nationwide claimsbased study from South Korea. medRxiv

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease

Large population study identifies drugs associated with reduced COVID-19 severity. medRxiv

Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals. medRxiv

Risk and severity of COVID-19 and ABO blood group in transcatheter aortic valve patients. medRxiv

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a

COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: A single-centre cohort study

Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study

Impact of Hypertension on Progression and Prognosis in Patients with COVID-19: A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China. medRxiv

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Meta-analysis of Effect of Statins in Patients with COVID-19

Considerations for Statin Therapy in Patients with COVID-19

Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome

Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications

Statins in COVID-19: is there any foundation?

Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

Steroids and statins: an old and a new anti-inflammatory strategy compared